Featured Research

from universities, journals, and other organizations

Human Fats: A Link Between Leprosy And Atherosclerosis?

Date:
July 17, 2008
Source:
Journal of Clinical Investigation
Summary:
Leprosy is caused by the microbe Mycobacterium leprae, which lives inside cells and survives by both evading the immune system and using human fat molecules (lipids) to promote its growth and virulence.

Leprosy is caused by the microbe Mycobacterium leprae, which lives inside cells and survives by both evading the immune system and using human fat molecules (lipids) to promote its growth and virulence.

A link between these two factors influencing M. leprae survival in the lesions that characterize disease in individuals with the lepromatous form of human leprosy (L-lep) has now been uncovered by Robert Modlin and colleagues, at UCLA David Geffen School of Medicine, Los Angeles.

In the study, expression of genes containing the information for making proteins involved in lipid metabolism (the production and breakdown of lipids) was observed in human L-lep lesions. Consistent with this, the lipid-laden cells (specifically macrophages) in human L-lep lesions that are known to harbor M. leprae were found to accumulate human lipids known as oxidized phospholipids.

Further in vitro analysis indicated that some of these oxidized phospholipids inhibited innate immune responses. The accumulation of macrophages laden with human oxidized phospholipids in L-lep lesions is strikingly similar to what is observed in the lesions that narrow the blood vessels in the disease atherosclerosis -- a common disease of the major arterial blood vessels that can result in heart attack or stroke.

These similarities have led the authors to suggest that in both microbial infection and atherosclerosis there is a link between innate immunity and human lipid metabolism.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. Journal of Clinical Investigation, July 18, 2008

Cite This Page:

Journal of Clinical Investigation. "Human Fats: A Link Between Leprosy And Atherosclerosis?." ScienceDaily. ScienceDaily, 17 July 2008. <www.sciencedaily.com/releases/2008/07/080717180102.htm>.
Journal of Clinical Investigation. (2008, July 17). Human Fats: A Link Between Leprosy And Atherosclerosis?. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/07/080717180102.htm
Journal of Clinical Investigation. "Human Fats: A Link Between Leprosy And Atherosclerosis?." ScienceDaily. www.sciencedaily.com/releases/2008/07/080717180102.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins